Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL105348 | 1.00 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Hydrochloric Acid SCHEMBL25337897 | 0.98 | NR1H2 (0.46) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Piperazine SCHEMBL28853588 | 0.97 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL28002373 | 0.97 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Acetic Acid SCHEMBL28827133 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Urea SCHEMBL4467391 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| Acetic Acid SCHEMBL28060582 | 0.95 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL31540 | 0.90 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD | |
| SCHEMBL2898103 | 0.90 | HPGD (0.48) | NR1H2USP2SMN1; SMN2MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | claimed |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | claimed |
| EP-4476205-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | Genentech Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| CN-118574820-A | Method for synthesizing quinazoline compounds | 基因泰克公司 | 2024-08-30 | — | — | CN | claimed |
| US-12071422-B2 | Process for synthesis of quinazoline compounds | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | claimed |
| CN-117903117-A | Preparation method of KRAS G12C inhibitor divarasib | 云南万宏医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-115466259-B | Preparation method of KRAS G12C inhibitor sotorubin | 山东大学 | 2023-12-05 | — | — | CN | claimed |
| EP-4234546-A2 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2023150653-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | claimed |
| CN-115466259-A | Preparation method of KRAS G12C inhibitor sotoxib | 山东大学 | 2022-12-13 | — | — | CN | claimed |
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114057654-A | Preparation method of (S) -1-Boc-3-methylpiperazine | 苏州艾缇克药物化学有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113754579-A | Preparation method of pyridine derivative | 正大天晴药业集团股份有限公司 | 2021-12-07 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-5712267-A | Carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY,. LIMITED (JP) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071422-B2 | Process for synthesis of quinazoline compounds | HCCS, NQO2, SQLE | NR1H2 2492/4885USP2 2729/4885SMN1; SMN2 3950/4885 |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NR1H2 4045/4885USP2 2323/4885SMN1; SMN2 3898/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | NR1H2 2492/4885USP2 2729/4885SMN1; SMN2 3950/4885 |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | NR1H2 3929/4885USP2 2447/4885SMN1; SMN2 2239/4885 |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NR1H2 3929/4885USP2 2447/4885SMN1; SMN2 2239/4885 |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | NR1H2 4045/4885USP2 2323/4885SMN1; SMN2 3898/4885 |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, BRAF | NR1H2 2503/4885USP2 1581/4885SMN1; SMN2 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.